Exposure-response analyses of cabozantinib in patients with metastatic renal cell cancer

Autor: Krens, S.D., Erp, N.P. van, Groenland, S.L., Moes, D.J.A.R., Mulder, S.F., Desar, I.M.E., Hulle, T. van der, Steeghs, N., Herpen, C.M.L. van

Publikováno v: BMC Cancer, 22, 1
BMC Cancer, 22
BMC Cancer, 22(1). BMC

AimIn the registration trial, cabozantinib exposure ≥ 750 ng/mL correlated to improved tumor size reduction, response rate and progression free survival (PFS) in patients with metastatic renal cell cancer (mRCC). Because patients in routine care of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b26b56a4ae9ad65f28be003310defc6

Pulmonary Lymphangitis Carcinomatosis of Clear Cell Renal Cell Carcinoma After Angiogenesis Inhibition

Autor: Kats-Ugurlu, G., Herpen, C.M. van, Mulder, S.F., Prokop, M., Waal, R.M. de, Mulders, P.F.A., Krieken, J.H.J.M. van, Oosterwijk, E., Leenders, W.P.

Publikováno v: Archives of Surgery and Clinical Case Reports, 51

Item does not contain fulltext

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6520dde3560fa85a32f262ff0640c9e
https://hdl.handle.net/2066/215975

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib

Autor: Lankheet, N.A.G., Desar, I.M.E., Mulder, S.F., Burger, D.M., Kweekel, D.M., Herpen, C.M.L. van, Graaf, W.T.A. van der, Erp, N.P. van

Publikováno v: British Journal of Clinical Pharmacology, 83, 2195-2204
British Journal of Clinical Pharmacology, 83, 10, pp. 2195-2204
British Journal of Clinical Pharmacology, 83(10), 2195-2204

Item does not contain fulltext AIM: Fixed dose oral tyrosine kinase inhibitors imatinib, sunitinib and pazopanib show a high interpatient variability in plasma exposure. A relationship between plasma exposure and treatment outcome has been establishe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::683e9dab8c3fb42921438360a34b817b
https://doi.org/10.1111/bcp.13327

Biological Effects After Discontinuation of VEGFR Inhibitors in Metastatic Renal Cell Cancer

Autor: Boers-Sonderen, M.J., Desar, I.M.E., Fütterer, J.J., Mulder, S.F., Geus-Oei, L.F. de, Mulders, P.F.A., Graaf, W.T.A. van der, Oyen, W.J.G., Herpen, C.M.L. van

Publikováno v: Anticancer Research, 35, 10, pp. 5601-6
Anticancer Research, 35, 5601-6

Item does not contain fulltext AIM: To gain greater insight into the biological mechanisms occurring shortly after discontinuation of VEGFR TKIs treatment because of progressive disease (PD). PATIENTS AND METHODS: Sixteen patients with PD during trea

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::bb587091709444f5417c63efa7bc8819
https://hdl.handle.net/2066/154645